Upcoming events

Boston Scientific announces U.S. FDA approval of EMBLEM™ MRI S-ICD system

Approval grants MR-Conditional labeling to all EMBLEM S-ICD systems, expands ImageReady™ portfolio.

MARLBOROUGH, Mass., Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling for all previously implanted EMBLEM S-ICD Systems. The new EMBLEM MRI S-ICD System is the latest addition to the company's growing line of ImageReady™ MR-conditional devices, which allow patients to undergo magnetic resonance imaging (MRI) safely.

The EMBLEM S-ICD System is a proven treatment option for patients at risk of sudden cardiac arrest, that leaves the heart and vasculature untouched, thus reducing the risk of complications associated with conventional transvenous implantable cardioverter-defibrillator leads.

"Now with FDA approval, patients receiving the EMBLEM MRI S-ICD System, as well as patients who previously were implanted with an EMBLEM S-ICD System, have reassurance they can safely undergo MR scans while remaining protected from cardiac arrest," said Kenneth Stein, M.D., chief medical officer, Rhythm Management, Boston Scientific.

Boston Scientific received CE Mark for the EMBLEM MRI S-ICD System earlier this year and began commercialization in Europe in June. In addition to MR-conditional labeling, the device introduces two new features to the market – SMART Pass technology and Atrial Fibrillation (AF) Monitor™. The SMART Pass technology, also being added to previously implanted EMBLEM S-ICD Systems through a software update, increases the accuracy of the INSIGHT™ Algorithm to help ensure patients receive appropriate therapy from the device only when necessary. The AF Monitor feature is a detection tool designed to alert physicians after the identification of AF so they can make more informed treatment decisions for their patients.

Earlier this year, the company received FDA approval for the ImageReady MR-Conditional Pacing System, which includes ACCOLADE™ MRI and ESSENTIO™ MRI pacemakers as well as INGEVITY™ MRI pacing leads, designed to treat bradycardia. Patients implanted with the full system are able to receive full-body MR scans in a 1.5 Tesla environment when conditions of use are met. Additionally, the company is actively pursuing MRI compatibility for their currently approved implanted cardiac defibrillation and cardiac resynchronization therapy systems via the global ENABLE MRI study.

For more information on the EMBLEM S-ICD Systems visit www.bostonscientific.com/sicd.

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Source: Boston Scientific Corporation